Roche Advances Hemophilia Gene Therapy in Phase III, Terminates Another
TL;DR Summary
Roche has announced the removal of RG6358, or SPK-8016, from its gene therapy pipeline for hemophilia A, while initiating a Phase III trial for RG6357, or SPK-8011. The company plans to open enrollment for the study, named Keystone1, later this year.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
57%
95 → 41 words
Want the full story? Read the original article
Read on Endpoints News